Since increased cholesterol level is correlated with enhancement of Aβ (as observed in the present study) and beneficial effects of statins as inhibitors of HMG-CoA reductase (17) in reducing symptoms of AD pathology has already been reported, it is proposed that dysregulation in the expression of the genes encoding proteins for cholesterol-metabolizing and transport pathways may contribute in AD pathology. Here, HMGCR is linked to Alzheimer disease.